CVS Health (CVS) Stock Forecast & Price Target

CVS Health is supported by a diversified healthcare model that combines retail pharmacy, a leading PBM processing about 2 billion adjusted claims annually, a top-tier insurer serving about 26 million medical members, and growing primary care through Oak Street Health. Its fundamentals are improving across the enterprise, with broad-based earnings growth, stronger Medicare Advantage margins, durable pharmacy profit growth, and cash generation of about $4.7 billion in quarterly operating cash flow and at least $15.5 billion for the full year. The planned separation in early 2028 could sharpen execution and simplify the story, while the enterprise still appears capable of delivering resilient EPS growth, buybacks, and value from complementary businesses despite regulatory noise.

CVS Health is facing a negative setup because its operating recovery is being pressured by multiple overlapping headwinds: an early-2028 separation adds uncertainty, while Aetna is still in a multi-year margin recovery and HSS faces 340B pressure. Caremark’s PBM remains strategically important, but intense competition, contract-retention pressure, and regulatory risk around PBM reform and 340B could weaken growth and margins, including a possible ~$90MM annualized headwind in a worst-case 2027 scenario. Retail pharmacy also faces declining reimbursement, fixed-cost leverage, consumer softness, and digital competition, which together could limit profit expansion even as it serves about 26 million medical members and processes roughly 2 billion adjusted claims annually.